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Background
ADXS11-001 immunotherapy is a live attenuated Lis-
teria monocytogenes (Lm) bioengineered to secrete a
tLLO-HPV-16-E7 fusion protein targeting HPV-trans-
formed cells. The Lm vector serves as its own adjuvant
and infects APC where it cross presents HPV-E7-tLLO
fusion peptide, stimulating MHC class 1 and 2 pathways
resulting in HPV-E7 specific T cell immunity. Lm-LLO-
E7-015 (Clinical Trials Registry India #CTRI/2010/091/
001232), is a randomized Phase II study designed to
evaluate the safety and efficacy of ADXS11-001 +/- Cis-
platin in patients with recurrent cervical cancer in India.
Methods
110 patients were randomized to either 3 doses of
ADXS11-001 at 1 × 109 cfu or 4 doses of ADXS11-001
at 1 × 109 cfu with Cisplatin chemotherapy (40 mg/m2,
weekly x5). Naproxen and oral Promethazine were given
as premedications. Patients received CT scans at base-
line and 3, 6, 9, 12 and 18 months. The primary end-
point was overall survival.
Results
Final 12-month survival was 32% (35/109), 18-month
survival was 22% (24/109) and 24-month survival was
18% (16/91). The response rate was 11% (5 CRs and 6
PRs/109) with tumor responses observed in both treat-
ment arms; 31 additional patients had stable disease ≥3
months, for a disease control rate of 38% (42/109).
Average duration of response in both treatment groups
was 9.5 months. Long term survivors (LTS; ≥18 months)
included patients with tumor shrinkage and patients
with increased tumor burden as their best tumor
response overall; 8% (2/24) of LTS failed at least two
prior treatments; and 25% (3/11) of LTS were ECOG
performance status 2 at baseline. Activity against differ-
ent high-risk HPV strains was observed. The addition of
Cisplatin to ADXS11-001 did not improve survival or
tumor response over ADXS11-001 alone but contributed
to toxcity. Baseline ECOG performance status, type of
prior therapy, or aggressiveness of disease had no signif-
icant effect on survival or tumor response. ADXS11-001
was well tolerated as 62% (68/109) of patients reported
no adverse events and 38% (41/109) of patients reported
only mild transient adverse events (G1-2) that occurred
on the day of infusion. The incidence of SAEs possibly
related/ related to ADXS11-001 was 1% G3 (0% G4-5).
Conclusions
ADXS11-001 appears to have significant clinical activity
in patients with recurrent cervical cancer. The observed
prolonged survival, objective tumor responses, and stabi-
lization of recurrent disease compare favorably with
more toxic chemotherapy treatment options and sup-
port ADXS11-001 as an active agent in the treatment of
cervical cancer.
Authors’ details
1Advaxis. Inc, NJ, USA. 2Central India Cancer Research Institute, Nagpur,
Maharashtra, India. 3Ruby Hall Clinic, Maharashtra, India. 4Tata Memorial
Hospital, Maharashtra, India. 5Curie Manavata Cancer Center, Maharashtra,
India. 6MV Hospital and Research Center, Chennai, Tamil Nadu, India. 7Dr.
Kamakshi Memorial Hospital, Chennai, Tamil Nadu, India. 8Smt. Kashibai
Navale Medical College and General Hospital, Pune, Maharashtra, India.
9Christian Medical College Vellore, Vellore, Tamil Nadu India. 10Chittaranjan
National Cancer Institute, Kolkata, West Bengal, India.1Advaxis. Inc, NJ, USA
Full list of author information is available at the end of the article
Petit et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P92
http://www.immunotherapyofcancer.org/content/2/S3/P92
© 2014 Petit et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P92
Cite this article as: Petit et al.: ADXS11-001 immunotherapy targeting
HPV-E7: final results from a Phase II study in Indian women with
recurrent cervical cancer. Journal for ImmunoTherapy of Cancer 2014
2(Suppl 3):P92.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Petit et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P92
http://www.immunotherapyofcancer.org/content/2/S3/P92
Page 2 of 2
